OneChain Immunotherapeutics (OCI), member of CataloniaBio & HealthTech, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA)to OC-1, a CAR T therapy against for the treatment of acute lymphoblastic leukemia (ALL), an aggressive subtype of T-cell leukemia. The company, which is part of the 1st generation of companies accelerated in the BCN Health Booster, has already started the CARxALL clinical trial to evaluate the safety and effectiveness of the product in humans. 

Aptadel Therapeutics, member of CataloniaBio & HealthTech, has named Gisela Lorente, to date the chief scientific officer, as the company’s new CEO. In this new period as CEO of Aptadel, the scientist and entrepreneur takes on the management of leading the spin-off’s strategic plan, focusing on its growth and profitability, as well as the challenge of making it a renowned company in the treatment of childhood cancer with RNA therapies. 

Amgen, member of CataloniaBio & HealthTech, has completed the acquisition of Horizon Therapeutics plc for $116.50 per action, representing a transaction value of approximately $27.8M. 

Renalyse, a CataloniaBio & HealthTech member, has concluded an investment round led by the Mind the Gap program of the Botín Foundation, with participation from GENESIS Ventures and the Eurostars program. In this manner, Renalyse has secured 1 M€ that will be allocated towards the industrialization and certification of its Chronic Kidney Disease diagnostic and monitoring device.

Onalabs Inno-Hub, the startup, a member of CataloniaBio & HealthTech, pioneer in the the development of medical devices capable of reading, measuring, and monitoring physical and biochemical physical and biochemical parameters of the skin through the sweat, has announced the successful completion of a capital increase of 1.8 million euros, thus multiplying its valuation by x2 in the short term of one year.

ADmit Therapeutics has secured a €5.4 million equity round with Clave Capital as the lead investor, with significant support from the EIC Fund and the Alzheimer's Drug Discovery Foundation (ADDF) Diagnostics Accelerator (DxA), alongside other investors such as Lavanda Ventures, Ship2B and WA4Steam. This funding round will enable the company to obtain CE marking and FDA approval for the commercialization of MAP-AD in Europe and the United States.

COMSER, a CataloniaBio & HealthTech member, highly specialized in services for the development and manufacture of lyophilized injectable drugs, announces the launch of an innovative technology to monitor product quality during the process. LyoFlow® has been developed by COMSER, within the framework of a research project initiated five years ago.

CaixaForum Macaya hosted today the debate session “UnConference 2023. Advanced therapies. An innovative market capable of improving the quality of life", organized by the organization CataloniaBio & HealthTech and in which more than 120 entrepreneurs and managers from the health sector have participated. 

Oncoheroes, member of CataloniaBio & HealthTech, announces that the US Food and Drug Administration (FDA) has allowed them to move forward with research on two of their potential paediatric oncology drugs, volasertib and dovitinib. This success reflects their unwavering commitment to pioneering therapies for children battling cancer. 

GoodGut, member of CataloniaBio & HealthTech, together with the Spanish Association of Specialists in Occupational Medicine (AEEMT) have announced a collaboration agreement to introduce digestive health as a new paradigm in occupational health.

Vytrus Biotech, member of CataloniaBio & HealthTech, has joined the Manifesto for an Economy with Purpose promoted by the organisation Respon.cat in view of the new role of companies as transforming agents and drivers of change in society and the world. 

Reig Jofre, member of CataloniaBio & HealthTech, has appointed Alex Sanfeliu as Global Head of Pharmaceutical Technologies Business Unit. He has a high responsibility in the commercial and strategic field in the pharmaceutical industry. He has worked in several countries such as the UK, France and Switzerland and has worked for international companies, including Novartis.  

Palex Medical, a national leader in precision oncology, and Inbiomotion, a spin-off of IRB Barcelona and ICREA, have signed an agreement to start marketing MAF-TEST®, initially in Spain and Portugal.

Catalonia and Castilla-La Mancha are the autonomous communities that benefited most from the total number of grants proposed, including two CataloniaBio & HealthTech companies: Leanbio, Medichem and Reig Jofre.

L’Hospital Vall d’Hebron i l’Hospital Clínic de Barcelona figuren entre els hospitals del món més especialitzats, segons el ‘World's Best Specialized Hospitals 2024’ i entre els més smart, segons el ‘World's Best Smart Hospitals 2024’, tots dos atorgats per Newsweek i Statista.

L’empresa health-tech InBrain Neuroelectronics, membre de CataloniaBio& HealthTech i dedicada al desenvolupament de la primera plataforma neuralintel·ligent basada en grafè del món, ha anunciat que el seu sistemaintel·ligent de modulació de circuits neuronals ha obtingut la Designació deDispositiu Innovador (Breakthrough Device Designation, BDD) de la U.S. Food & DrugAdministration (FDA) com a teràpia complementària per tractar la malaltia deParkinson. 

HOFFMANN EITLE Madrid & Barcelona is celebrating 10 years of advising companies in the biotechnology and health ecosystem in the creation, protection and defence of their Intellectual Property (IP) rights.

CataloniaBio & HealthTech serà present alBIOSPAIN, el major esdeveniment biotecnològic organitzat per una associaciónacional de bioindústria a Europa i un dels majors del món, tant pel nombre dereunions one-to-one com per la xifra d’empreses participants. El 34%dels delegats procedeixen de fora d’Espanya. 

Asabys, member of CataloniaBio & HealthTech, today announced the entry of the Catalan Institute of Finance (ICF) into its new venture capital fund, Sabadell Asabys Health Innovation Investments II (Sabadell Asabys II), with a stake of €10 million. 

Invivo Capital, member of CataloniaBio & HealthTech, is one of the investors in the €65 million Series A financing announced by Corteria Pharmaceuticals, oversubscribed and co-leadership by US investment firm OrbiMed.